Abstract
Mucositis is a side effect associated with the use of chemotherapy, and has a significant impact on the quality of life. Mucositis, by definition, refers to the inflammation of the mucosa and occurs throughout the alimentary tract from the mouth to anus. Nuclear Factor kappa B (NFκB) encompasses a family of transcription factors, which upregulate pro-inflammatory cytokines. These are recognized as key targets in developing therapeutic interventions for chemotherapy-induced mucositis, and cyclooxygenase (COX)-2 inhibition may also be beneficial in reducing the severity and duration. This review focuses on the pathobiology of chemotherapy-induced oral and gastrointestinal mucositis and recent research examining the role of agents with anti-inflammatory activity in treatment and prevention of the condition. We consider agents in clinical use as well as some others under current investigation including plant-derived and other natural medicines.
Keywords: Mucositis, chemotherapy, gastrointestinal, inflammation, anti-inflammatory, natural agents.
Current Pharmaceutical Design
Title:Advances in the Use of Anti-inflammatory Agents to Manage Chemotherapy-induced Oral and Gastrointestinal Mucositis
Volume: 24 Issue: 14
Author(s): Vaishnavi J. Mahendran, Andrea M. Stringer, Susan J. Semple, Yunmei Song and Sanjay Garg*
Affiliation:
- School of Pharmacy and Medical Sciences, Sansom Institute for Health Research, University of South Australia, Adelaide,Australia
Keywords: Mucositis, chemotherapy, gastrointestinal, inflammation, anti-inflammatory, natural agents.
Abstract: Mucositis is a side effect associated with the use of chemotherapy, and has a significant impact on the quality of life. Mucositis, by definition, refers to the inflammation of the mucosa and occurs throughout the alimentary tract from the mouth to anus. Nuclear Factor kappa B (NFκB) encompasses a family of transcription factors, which upregulate pro-inflammatory cytokines. These are recognized as key targets in developing therapeutic interventions for chemotherapy-induced mucositis, and cyclooxygenase (COX)-2 inhibition may also be beneficial in reducing the severity and duration. This review focuses on the pathobiology of chemotherapy-induced oral and gastrointestinal mucositis and recent research examining the role of agents with anti-inflammatory activity in treatment and prevention of the condition. We consider agents in clinical use as well as some others under current investigation including plant-derived and other natural medicines.
Export Options
About this article
Cite this article as:
Mahendran J. Vaishnavi, Stringer M. Andrea, Semple J. Susan, Song Yunmei and Garg Sanjay*, Advances in the Use of Anti-inflammatory Agents to Manage Chemotherapy-induced Oral and Gastrointestinal Mucositis, Current Pharmaceutical Design 2018; 24 (14) . https://dx.doi.org/10.2174/1381612824666180409093918
DOI https://dx.doi.org/10.2174/1381612824666180409093918 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Therapy of Chronic Hepatitis C Virus Infection in HIV Co-Infected People
Current Pharmaceutical Design DNA Vaccine and the CNS Axonal Regeneration
Current Pharmaceutical Design Does Phosphodiesterase 11A (PDE11A) Hold Promise as a Future Therapeutic Target?
Current Pharmaceutical Design Microwave-Assisted Claisen and Aza-Claisen Rearrangements
Mini-Reviews in Organic Chemistry The Janus Face of Adenosine: Antiarrhythmic and Proarrhythmic Actions
Current Pharmaceutical Design A Balanced View of Efficacy and Safety of Aspirin in Cardiovascular Diseases
Current Pharmaceutical Design Drug Withdrawals in the United States: A Systematic Review of the Evidence and Analysis of Trends
Current Drug Safety Fragment-Based Optimization of Small Molecule CXCL12 Inhibitors for Antagonizing the CXCL12/CXCR4 Interaction
Current Topics in Medicinal Chemistry Discovery of Novel Cell Proliferation-Enhancing Gene by Random siRNA Library Based Combinatorial Screening
Combinatorial Chemistry & High Throughput Screening Viral and Non-Viral Methods to Genetically Modify Dendritic Cells
Current Gene Therapy Protection and Restitution of Gut Barrier by Probiotics: Nutritional and Clinical Implications
Current Nutrition & Food Science Vicious Cycles Within the Neuropathophysiologic Mechanisms of Alzheimers Disease
Current Alzheimer Research Genetic Mapping of Pharmacogenetic Regulatory Variation
Current Pharmaceutical Design Variability in the Response to Non-pharmacological Treatments in Patients with Cardiovascular Diseases
Current Pharmacogenomics and Personalized Medicine Sensitivity of SARS/MERS CoV to Interferons and Other Drugs Based on Achievable Serum Concentrations in Humans
Infectious Disorders - Drug Targets Editorial
Inflammation & Allergy - Drug Targets (Discontinued) Perspectives for Drug Intervention in Amyloid Diseases
Current Drug Targets Multiple Functions of Generic Drugs: Future Perspectives of Aureolic Acid Group of Anti-Cancer Antibiotics and Non-Steroidal Anti-Inflammatory Drugs
Mini-Reviews in Medicinal Chemistry Evolution of Resistance to Cancer Therapy
Current Pharmaceutical Design Editorial [Hot Topic: Plasminogen Activator Inhibitor-1 (Guest Editor: Daniel A. Lawrence)]
Current Drug Targets